223 related articles for article (PubMed ID: 25003848)
1. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.
Uttervall K; Duru AD; Lund J; Liwing J; Gahrton G; Holmberg E; Aschan J; Alici E; Nahi H
PLoS One; 2014; 9(7):e101819. PubMed ID: 25003848
[TBL] [Abstract][Full Text] [Related]
2. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
3. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Weisel KC; Dimopoulos MA; Moreau P; Lacy MQ; Song KW; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Knop S; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel J
Haematologica; 2016 Jul; 101(7):872-8. PubMed ID: 27081177
[TBL] [Abstract][Full Text] [Related]
4. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
Dimopoulos MA; Delimpasi S; Katodritou E; Vassou A; Kyrtsonis MC; Repousis P; Kartasis Z; Parcharidou A; Michael M; Michalis E; Gika D; Symeonidis A; Pouli A; Konstantopoulos K; Terpos E; Kastritis E
Ann Oncol; 2014 Jan; 25(1):195-200. PubMed ID: 24356630
[TBL] [Abstract][Full Text] [Related]
5. [A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
An N; Li X; Shen M; Chen SL; Huang ZX
Zhonghua Nei Ke Za Zhi; 2016 Oct; 55(10):764-768. PubMed ID: 27686436
[No Abstract] [Full Text] [Related]
6. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
[TBL] [Abstract][Full Text] [Related]
7. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
Eleftherakis-Papapiakovou E; Kastritis E; Roussou M; Gkotzamanidou M; Grapsa I; Psimenou E; Nikitas N; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2011 Dec; 52(12):2299-303. PubMed ID: 22141916
[TBL] [Abstract][Full Text] [Related]
8. Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Maciocia N; Melville A; Cheesman S; Sharpley F; Ramasamy K; Streetly M; Jenner M; Benjamin R; Schey S; Maciocia P; Popat R; D'sa S; Rismani A; Cerner A; Yong K; Rabin N
Br J Haematol; 2017 Mar; 176(6):908-917. PubMed ID: 28211054
[TBL] [Abstract][Full Text] [Related]
9. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
Ho PJ; Moore EM; McQuilten ZK; Wellard C; Bergin K; Augustson B; Blacklock H; Harrison SJ; Horvath N; King T; Mollee P; Quach H; Reid C; Rosengarten B; Walker P; Wood EM; Spencer A
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e415-e424. PubMed ID: 31208889
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.
Li J; Zhou DB; Jiao L; Duan MH; Zhang W; Zhao YQ; Shen T
Clin Lymphoma Myeloma; 2009 Oct; 9(5):394-8. PubMed ID: 19858061
[TBL] [Abstract][Full Text] [Related]
11. A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment.
Liu A; Yang G; Geng C; Wang H; Li L; Li Y; Wu Y; Tian Y; Leng Y; Wang G; Gao W; Chen W
Acta Haematol; 2016; 135(3):140-5. PubMed ID: 26587903
[TBL] [Abstract][Full Text] [Related]
12. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Dimopoulos MA; Cheung MC; Roussel M; Liu T; Gamberi B; Kolb B; Derigs HG; Eom H; Belhadj K; Lenain P; Van der Jagt R; Rigaudeau S; Dib M; Hall R; Jardel H; Jaccard A; Tosikyan A; Karlin L; Bensinger W; Schots R; Leupin N; Chen G; Marek J; Ervin-Haynes A; Facon T
Haematologica; 2016 Mar; 101(3):363-70. PubMed ID: 26659916
[TBL] [Abstract][Full Text] [Related]
13. Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients.
Chen X; Luo X; Zu Y; Issa HA; Li L; Ye H; Yang T; Hu J; Wei L
J Clin Lab Anal; 2020 Sep; 34(9):e23416. PubMed ID: 32710448
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.
Berdeja J; Jagannath S; Zonder J; Badros A; Kaufman JL; Manges R; Gupta M; Tendolkar A; Lynch M; Bleickardt E; Paliwal P; Vij R
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):129-38. PubMed ID: 26795075
[TBL] [Abstract][Full Text] [Related]
15. Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment.
Sharma R; Jain A; Jandial A; Lad D; Khadwal A; Prakash G; Nada R; Aggarwal R; Ramachandran R; Varma N; Malhotra P
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):626-634. PubMed ID: 35610119
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function.
Chen J; Liu H; Li L; Liu Z; Song J; Wang G; Wang H; Ruan E; Ding K; Shao Z; Fu R
J Clin Lab Anal; 2019 Jun; 33(5):e22888. PubMed ID: 31004381
[TBL] [Abstract][Full Text] [Related]
17. Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Liwing J; Uttervall K; Lund J; Aldrin A; Blimark C; Carlson K; Enestig J; Flogegård M; Forsberg K; Gruber A; Haglöf Kviele H; Johansson P; Lauri B; Mellqvist UH; Swedin A; Svensson M; Näsman P; Alici E; Gahrton G; Aschan J; Nahi H
Br J Haematol; 2014 Mar; 164(5):684-93. PubMed ID: 24313224
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
Bridoux F; Chen N; Moreau S; Arnulf B; Moumas E; Abraham J; Desport E; Jaccard A; Fermand JP
Cancer Chemother Pharmacol; 2016 Jul; 78(1):173-82. PubMed ID: 27286995
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA
Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
Oehrlein K; Langer C; Sturm I; Pönisch W; Hahn-Ast C; Kuhn S; Weisel KC
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):191-6. PubMed ID: 22341857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
